Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Cell Biol Int. 2023 Nov 10. doi: 10.1002/cbin.12098. Online ahead of print.ABSTRACTMesenchymal stem cells (MSCs) are recognized for their remarkable ability to differentiate into multiple cell types. They are also known to possess properties that can fight cancer, leading to attempts to modify MSCs for use in anticancer treatments. However, MSCs have also been found to participate in pathways that promote tumor growth. Many studies have been conducted to explore the potential of MSCs for clinical applications, but the results have been inconclusive, possibly due to the diverse nature of MSC populations. Furthermore, the conflicting roles of MSCs in inhibiting tumors and promoting tumor growth hinder their adaptation to anticancer therapies. Antitumorigenic and protumorigenic properties of MSCs in urological cancers such as bladder, prostate, and renal are not as well established, and data comparing them are still limited. MSCs hold significant promise as a vehicle for delivering anticancer agents and suicide genes to tumors. Presently, numerous studies have concentrated on the products derived from MSCs, such as extracellular vesicles (EVs), as a form of cell-free therapy. This work aimed to review and discuss the current knowledge of MSCs and their EVs in urological cancer therapy.PMID:37947445 | DOI:10.1002/cbin.12098

Source: Cell Biology International - November 10, 2023 Category: Cytology Authors: Mohamed J Saadh Hayaa M Alhuthali Oblitas Gonzales An íbal Jos é Ander Asenjo-Alarcón Dhuha Ghassan Younus Ahmed Alhili Zainab Hussein Adhab Ohud Alsalmi Amal F Gharib Renzon Daniel Cosme Pecho Reza Akhavan-Sigari Source Type: research